Combination treatment for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with triple-negative breast cancer (a type of breast cancer that tests negative for estrogen, progesterone, and HER2).
- You must have had at least 2 prior treatments for advanced or metastatic breast cancer, including a taxane-based chemotherapy.
- You must be 19 years of age or older.
- You must be able to perform daily activities without significant limitation (ECOG performance status 0 or 1).
- You must have at least one tumor that can be measured on a CT scan.
- If you have had brain metastases, they must be treated and stable, without current symptoms requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antibody-drug conjugates (targeted cancer-killing drugs) given one after the other to see if they work well for triple-negative breast cancer with low HER2. It aims to provide a new treatment option that may slow the cancer's growth.
This study compares two combinations of drugs for people with a specific type of advanced breast cancer called triple-negative, which is PD-L1 positive. One combination uses sacituzumab govitecan, a targeted drug, with toripalimab, an immunotherapy. The other uses toripalimab with nab-paclitaxel, a chemotherapy. The goal is to see which combination works better.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.